Displaying drugs 2176 - 2200 of 3153 in total
CRA_9076
Experimental
AZD-9056
AZD9056 has been used in trials studying the basic science and treatment of Rheumatoid Arthritis.
Investigational
CC-90001
Investigational
SCH-900271
Sch 900271 has been used in trials studying the treatment of Mixed Hyperlipidemia and Primary Hypercholesterolemia.
Investigational
BMS-908662
BMS-908662 has been used in trials studying the treatment of Melanoma and Colorectal Cancer.
Investigational
CMG901
CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.
Investigational
Dapoxetine
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation...
Investigational
Matched Mixtures name: … TADA PLUS 30/20 MG FILM KAPLI TABLET ,8 ADET ... DAPOKSEL 30 MG/50 MG FILM TABLET ,3 FILM TABLET ... DAPOXIL 30/50 MG FILM KAPLI TABLET,18 FILM KAPLI TABLET …
TP-508
TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Investigational
TNG908
TNG908 is a small molecule inhibitor of protein arginine methyl transferase 5 (PRMT5).
Investigational
JTC-801 free base
An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.
Investigational
RP-A501
RP-A501 is a gene therapy product consisting of a recombinant adeno-associated virus serotype 9 (rAAV9) capsid containing the human LAMP2B transgene (AAV9:LAMP2B), which encodes lysosome-associated membrane protein 2 (LAMP-2). It is being investigated for Danon disease.
Investigational
SNX-2112
SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
Investigational
Matched Description: … SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.[A253137] …
HZT-501
HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing...
Investigational
CAN-508
Experimental
CBP-501
Investigational
GTP-506
GTP-506 is a gene therapy formed by two vectors, a nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a therapeutic donor vector that inserts the OTC gene to provide the desired genetic correction.
Investigational
ANC-501
ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment of Adults With Major Depressive Disorder).
Investigational
OMS906
OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.
Investigational
Ifinatamab deruxtecan
Investigational
Bersanlimab
Bersanlimab is an investigational monoclonal antibody directed against intercellular adhesion molecule 1 (ICAM-1).
Investigational
NDI-5001
Investigational
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Displaying drugs 2176 - 2200 of 3153 in total